Latest / The Buyout Show with Fexingo: Private Equity, Roll-Ups, and Business Acquisitions / The Roll-Up Of Independent Optometrists
Transcript
- Lucas: If you have been watching the private equity playbook over the last eighteen months, you have noticed a distinct shift away from heavy industrial assets toward service-based healthcare. Specifically, we are seeing massive capital deployment into independent optometry practices. By October twenty-fifth, two thousand twenty-six, the trend lines for eye care consolidation are steeper than almost any other vertical. Luna: That is true. I was reading a report from the American Optometric Association yesterday that noted a forty percent increase in M&A activity for small to mid-sized eye clinics since early this year. It feels like the window for going it alone is closing fast. Lucas: And it is not just about volume. The economics of optical dispensing—the frames and lenses sold alongside medical exams—provide a recurring revenue stream that PE firms love. One firm recently acquired three practices in Ohio for roughly eighty million dollars, promising to double their EBITDA within five years through cross-selling and operational efficiency. Luna: Eighty million for three practices? That implies each location is valued at nearly thirty million. Those multiples seem incredibly high compared to traditional retail. Lucas: Exactly. You are paying for the patient database and the lease assignments. But here is the twist. Unlike dental service organizations which have faced antitrust scrutiny, eye care has remained largely unregulated by state boards regarding corporate ownership. This legal vacuum is why the capital is flowing in so aggressively right now. Luna: So the barrier to entry is lower for the buyers than it is for the doctors selling out. That changes the power dynamic significantly. Lucas: It does. And before we dig into the structural risks of this consolidation, I want to pause for a second. If these conversations have moved your work forward in some small way, consider supporting the show directly. Honestly, if today was worth a coffee to you, that's the link — buy me a coffee dot com slash fexingo — that's F. E. X. I. N. G. O. Your support keeps this ad-free and allows us to keep digging into these deals. Luna: Thanks for the support, everyone. It really helps us get deeper into the data without needing sponsor slots cluttering the airwaves. Lucas: Let's get back to the mechanics. When a private equity firm buys an independent optometrist, they rarely keep the original brand name. They strip it, rebrand it under a regional banner, and then immediately begin acquiring neighboring competitors to create a monopoly in that zip code. This is the classic roll-up strategy. Luna: But does the local community actually notice the difference? Or is it just a change on the door sign? Lucas: They notice. The biggest friction point is pricing transparency. Independent doctors often negotiate custom discounts with local frame suppliers. Once you join a national chain, you lose that leverage. You are forced to use the parent company's preferred vendor, which can raise the cost of frames by fifteen to twenty percent. Luna: That sounds like a classic margin squeeze disguised as efficiency. Who absorbs that cost? The patient or the insurance company? Lucas: Usually the patient, because vision insurance plans have strict annual caps. If the out-of-pocket cost for premium lenses goes up, many patients simply delay their exam. That is the counter-intuitive part of this trend. Consolidation should theoretically drive prices down through scale, but in fragmented markets like eye care, it often drives them up due to reduced competition. Luna: So the investor thesis relies on volume growth offsetting price sensitivity. They need more people buying glasses, not fewer. Lucas: Precisely. And they are betting on demographics. The population over fifty is growing rapidly, and that demographic spends the most on corrective lenses. It is a predictable, aging customer base. For a PE firm looking for stable cash flows in October twenty-twenty-six, that is gold. Luna: But what happens when those patients age out or pass away? Is there a replacement pipeline young enough to justify that initial eighty-million-dollar purchase? Lucas: That is the ten-year risk. These firms assume that younger demographics will adopt tele-optometry services or self-serve kiosks for basic prescriptions. They are trying to digitize the relationship to lower labor costs. But optics requires physical interaction. You cannot fully remote a cataract surgery consult. Luna: Right. There is a limit to how much technology can replace the human element in medical diagnostics. I wonder if that human capital retention is the weak link in these deals. Lucas: You hit the nail on the head. When a practice is bought, the key doctor usually stays on for two years under a non-compete. After that, they often leave to start their own thing again. This churn creates operational instability. The PE firm ends up spending millions recruiting locum tenens doctors just to keep the lights on. Luna: So they are buying a brand, but losing the actual expertise that makes the brand valuable. That seems like a fundamental flaw in the valuation model. Lucas: It is. And we are starting to see this play out in the financials. Several regional eye care groups filed for restructuring last quarter because their debt loads became unsustainable once the projected volume growth failed to materialize. They overpaid for the real estate and underestimated the staff turnover. Luna: I saw one of those filings. The credit rating agencies were pretty brutal about the liquidity crunch. It made me question whether healthcare roll-ups are still the safe haven they used to be. Lucas: They are never safe. They are just differently risky. The risk here is regulatory reversal. State legislatures are currently debating bills to restrict corporate ownership of medical practices. If those pass, the entire asset base of these pe backed chains could become unfinanceable overnight. Luna: That would be a hard stop. Imagine having hundreds of millions tied up in properties that no longer comply with state law. That sounds like a nightmare scenario for the limited partners. Lucas: It is. And yet, the deal flow continues. Why? Because the first movers are already entrenched. They have the leases signed, the vendors locked in, and the patient records migrated. New entrants cannot compete with that infrastructure. It creates a moat that lasts until the regulatory hammer drops. Luna: So it is a race against time. Win the market now, extract value, and exit before the rules change. Classic PE behavior. Lucas: Exactly. They are harvesting the current goodwill of independent doctors and converting it into liquid equity. The doctors who sell out today get a nice payout, but they lose control of their future earnings potential. It is a trade-off between immediate liquidity and long-term independence. Luna: For a doctor nearing retirement, that might be the rational choice. But for a young associate, it means they are joining a machine, not a practice. Lucas: That is the cultural shift. Younger clinicians are increasingly uncomfortable with corporate oversight. We are seeing a backlash forming among residents. Some are refusing to join dso affiliated hospitals or eye networks, preferring to stay in smaller groups even if the pay is lower. Luna: That resistance could slow the consolidation pace. If talent refuses to move, the roll-ups stall. Do you think the supply of willing sellers is drying up? Lucas: It is getting thinner. The best practices have already been sold. Now, PE firms are chasing lower-quality assets with higher debt or outdated equipment. The returns on those deals are much slimmer. You can’t apply the same multiple to a clinic that needs a roof repair. Luna: So the easy money has been made. The hard money is coming next. That usually means more failures. Lucas: Inevitably. We are moving from the consolidation phase to the optimization phase. That is where the real pain happens. You start cutting corners on maintenance, reducing marketing spend, and pushing staff harder. Patient satisfaction scores tend to drop during this stage. Luna: And if patient satisfaction drops, the referral network dries up. Doctors rely on primary care physicians to send them complex cases. If those PCPs lose trust in the network, the volume evaporates. Lucas: Correct. The ecosystem depends on trust. Corporate consolidation can erode that trust faster than it builds scale. It is a delicate balance. The firms that survive will be the ones that maintain local autonomy while centralizing backend operations. The ones that try to micromanage every exam will fail. Luna: So the lesson here is that you can scale the business, but you cannot scale the bedside manner. That remains a localized asset. Lucas: Absolutely. And that is why I think we will see some fragmentation return. As the big chains struggle with integration costs, smaller independent groups will find niches they ignored. Specialized pediatric eye care, for example, is still largely untouched by the major roll-ups. Luna: Niche specialization is the antidote to commoditization. If you offer something unique, you don't have to compete on price. Lucas: Right. The future of eye care might not be monolithic chains, but a hybrid model. Regional hubs for surgery, supported by smaller satellite clinics for routine exams. It’s a more efficient structure that preserves some local character. Luna: That sounds like a healthier market structure for both providers and patients. Less monopolistic pressure, more focus on specific needs. Lucas: I hope so. But for now, the checkbooks are still open. Investors are eager to put capital to work in healthcare, and optometry offers the perfect mix of recession-resistant demand and high-margin optical sales. Luna: Until the regulations catch up. Or until the patients vote with their wallets. Lucas: Or until the next crisis hits. In private equity, timing is everything. And right now, the clock is ticking on this particular roll-up cycle.